Neuron23

As 2024 comes to a close, we’re reflecting back on the incredible year we had as a company. From completing major milestones to spending quality time in and out of the office with the team, we have a lot to celebrate. We’re wishing everyone a wonderful holiday, and we can’t wait to come back strong in the new year to continue our work in creating precision medicines to fight debilitating diseases.

This week, we wrapped up another successful #toydrive in partnership with Samaritan House of San Mateo County. We are grateful for the efforts of our team and the staff/volunteers of Samaritan House for their dedication and support to help ensure a wonderful holiday season for more families in our community.

This month, we had the pleasure of listening in to our very own, Thomas DeMelfi, for another fireside chat. With a combined experience in global regulatory affairs, business development, and research across small and large #biotech and pharmaceutical companies, Tom was able to share insights into his robust background to provide a wealth of knowledge to the team. We look forward to continuing these fireside chats next year to learn more about our team and further build our relationships.

Please join us in welcoming Bonnie Early, Clinical Trial Manager, to Neuron23. We're so excited to have you on board, Bonnie! #NewHires #Neuron23

We are pleased to announce the initiation of dosing in our Phase 1 clinical trial of NEU-111 in healthy volunteers. NEU-111 is an oral allosteric tyrosine kinase 2 (TYK2) inhibitor, a JAK family protein that plays a key role in pathological immune signaling. This innovative approach could offer new hope for patients and create opportunities for strategic partnerships as we advance our robust pipeline in addressing both #neurological and #immunological conditions. Learn more below about NEU-111 and its significance for patients, the #systemicinflammation space, and Neuron23. https://lnkd.in/eMVnMGDd

This #Thanksgiving season, we took the opportunity to extend our gratitude to our dedicated team with a plentiful Thanksgiving lunch. Our teams' efforts continue to inspire us to make meaningful strides in our mission every day and we wouldn't be where we are today without them. We wish everyone a joyous holiday with friends and family!

The primary endpoint of our Phase 2 NEULARK clinical trial of NEU-411 incorporates a digital biomarker and smartphone-based solution developed by Roche Information Solutions (RIS), the Roche group focused on digital health solutions. Clinical development in #Parkinsons disease (PD) has historically been challenged by symptom variability that reduces the sensitivity and reliability of clinical outcome assessments. Potential benefits of the navify® digital biomarker solution include significantly greater frequency of data measurement and more objective and precise quantification of symptoms. Learn more about Neuron23’s usage of Roche’s digital biomarker and device in our PD clinical trial here: https://lnkd.in/gUTJXeB8

We're excited to share details about our Phase 2 NEULARK trial of NEU-411, a brain-penetrant, potent and selective inhibitor of #LRRK2, in people living with early #Parkinsons disease (PD). The NEULARK trial represents a significant #precisionmedicine advancement in how we can effectively identify and measure therapeutic impact in LRRK2-driven PD, estimated to affect up to 30% of people living with the disease. Listen in as Chief Medical Officer Sam Jackson, EVP of Drug Discovery Steve Wood, and Executive Director of Clinical and Digital Development Fatta B. Nahab MD, FAAN, FANA, discuss the importance of NEU-411 and how this innovative trial in PD differentiates itself. Our LRRK2 program is a key driver of innovation within our neuroimmunology pipeline, and we are on track to initiate this trial early in 2025. Read more here: https://lnkd.in/eShmssCC

The foundation of innovation is rooted in a dynamic, motivated, and well-educated workforce proficient in #STEM skills. In honor of #NationalSTEMDay, our team members shared some of their experiences in STEM to inspire the next generation to explore the exciting possibilities within this field. Check out responses from Anh Truong, Nathan Peterson, and David T. below!

Happy #Halloween from Neuron23! We celebrated the fall season with a costume party at the office. There's no better way to keep the team close than enjoying each other's company over good food and drinks. Check us out below and tell us which costume is your favorite.